ActiVein develops a patented, dual-action intravenous (IV) catheter that aims to replace the standard conventional "hospital IV line" by enabling both fluid infusion and blood withdrawal using a single vein over an entire hospitalization period, whereas the currently used device aims to allow, regularly, fluid infusion only.

ActiVein develops a patented, dual-action intravenous (IV) catheter that aims to replace the standard conventional "hospital IV line" by enabling both fluid infusion and blood withdrawal using a single vein over an entire hospitalization period, wher...Show all

Board Members

Competitors

Delcath has developed a system to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver. Using the Delcath system to deliver chemotherapy to the liver and cleanse the blood of the chemotherapy before its return from the liver into the patient's circulatory system protects other parts of the body from the harmful side-effects of chemotherapy. The Company believes that the use of the Delcath system in treatment of li...Show all

Bacchus Vascular, Inc. is a privately-held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis ...Show all